Ionis Pharmaceuticals (IONS) News Today $28.38 -0.30 (-1.05%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$30.11 +1.73 (+6.10%) As of 04/15/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period TD Cowen Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)April 15 at 8:42 PM | markets.businessinsider.comKennedy Capital Management LLC Boosts Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Kennedy Capital Management LLC increased its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 37.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 223,278 sApril 13 at 6:46 AM | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Acquired by Geode Capital Management LLCGeode Capital Management LLC lifted its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 0.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,687,248 shares of the company's stock after purchasing an additional 18,890April 13 at 4:39 AM | marketbeat.comQ1 Earnings Forecast for IONS Issued By HC WainwrightIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - HC Wainwright issued their Q1 2025 earnings estimates for Ionis Pharmaceuticals in a note issued to investors on Monday, April 7th. HC Wainwright analyst M. Kapoor forecasts that the company will earn ($1.04) per share for the quarter. HCApril 12, 2025 | marketbeat.comQ1 Earnings Estimate for IONS Issued By HC WainwrightApril 12, 2025 | americanbankingnews.comMorgan Stanley Keeps Their Hold Rating on Ionis Pharmaceuticals (IONS)April 11, 2025 | markets.businessinsider.comIonis Pharmaceuticals price target lowered to $52 from $55 at Morgan StanleyApril 11, 2025 | markets.businessinsider.comIonis Pharmaceuticals (NASDAQ:IONS) Upgraded by HC Wainwright to "Strong-Buy" RatingHC Wainwright upgraded Ionis Pharmaceuticals to a "strong-buy" rating in a research note on Monday.April 11, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Landscape Capital Management L.L.C.Landscape Capital Management L.L.C. lessened its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 59.6% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 10,270 shares of the company's stock after selling 15,165 shares during the quarter. LandscApril 10, 2025 | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Hits New 12-Month Low - Should You Sell?Ionis Pharmaceuticals (NASDAQ:IONS) Reaches New 1-Year Low - Here's What HappenedApril 9, 2025 | marketbeat.comCalifornia Public Employees Retirement System Decreases Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)California Public Employees Retirement System lessened its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 9.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 192,130 shares of the compApril 9, 2025 | marketbeat.comTrexquant Investment LP Cuts Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Trexquant Investment LP decreased its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 35.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 84,913 shares of the company's stock after sApril 8, 2025 | marketbeat.comDrugmaker Ionis Pharmaceuticals Garners Analyst Praise For 'Pipeline Depth'April 8, 2025 | benzinga.comHC Wainwright & Co. Initiates Coverage of Ionis Pharmaceuticals (IONS) with Buy RecommendationApril 8, 2025 | msn.comIonis Pharmaceuticals initiated with a Buy at H.C. WainwrightApril 7, 2025 | msn.comRhenman & Partners Asset Management AB Has $7.43 Million Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Rhenman & Partners Asset Management AB boosted its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 9.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 212,500 shares of the company's stock after buying an additioApril 7, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Schroder Investment Management GroupSchroder Investment Management Group trimmed its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 98.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 100,659 shares of the company's stock afterApril 7, 2025 | marketbeat.comIonis Pharmaceuticals' (IONS) "Buy" Rating Reiterated at GuggenheimApril 6, 2025 | americanbankingnews.comGuggenheim Reiterates Buy Rating for Ionis Pharmaceuticals (NASDAQ:IONS)Guggenheim reaffirmed a "buy" rating on shares of Ionis Pharmaceuticals in a research report on Thursday.April 5, 2025 | marketbeat.comWells Fargo Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)April 5, 2025 | markets.businessinsider.comNorges Bank Makes New Investment in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Norges Bank purchased a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,714,762 shares of the company's stock, valuApril 5, 2025 | marketbeat.comTD Cowen Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)April 3, 2025 | markets.businessinsider.comIonis Pharmaceuticals (NASDAQ:IONS) Stock Price Down 4.6% - Here's What HappenedIonis Pharmaceuticals (NASDAQ:IONS) Shares Down 4.6% - Here's WhyApril 3, 2025 | marketbeat.comIonis to host expert panel discussion on sHTGApril 3, 2025 | businesswire.comGroupama Asset Managment Boosts Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Groupama Asset Managment raised its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 11.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,017,191 shares of the company's stock after buyinApril 2, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Tweedy Browne Co LLCTweedy Browne Co LLC trimmed its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 6.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,248,863 shares of the company'sApril 2, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Clearbridge Investments LLCClearbridge Investments LLC lowered its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 4.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,618,220 shares of the company's stockApril 2, 2025 | marketbeat.comPictet Asset Management Holding SA Cuts Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Pictet Asset Management Holding SA cut its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 52.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 620,798 shares of the company'sApril 2, 2025 | marketbeat.comVanguard Group Inc. Has $575.88 Million Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Vanguard Group Inc. increased its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 9.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 16,472,539 shares of the company's stock after purchasing an additional 1April 2, 2025 | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Hits New 12-Month Low - Here's WhyIonis Pharmaceuticals (NASDAQ:IONS) Hits New 12-Month Low - Here's WhyApril 1, 2025 | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Now Covered by Analysts at Redburn AtlanticRedburn Atlantic started coverage on shares of Ionis Pharmaceuticals in a research report on Monday. They set a "neutral" rating and a $39.00 price objective on the stock.April 1, 2025 | marketbeat.comIonis Pharmaceuticals initiated with a Neutral at Redburn AtlanticMarch 31, 2025 | markets.businessinsider.comRedburn Atlantic Initiates Coverage of Ionis Pharmaceuticals (IONS) with Neutral RecommendationMarch 31, 2025 | msn.comAssessing Ionis Pharmaceuticals: Insights From 8 Financial AnalystsMarch 31, 2025 | benzinga.comIonis to present at upcoming investor conferencesMarch 31, 2025 | businesswire.comKLP Kapitalforvaltning AS Acquires Shares of 29,200 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)KLP Kapitalforvaltning AS bought a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 29,200 shares of the company's stMarch 31, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Artisan Partners Limited PartnershipArtisan Partners Limited Partnership trimmed its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 88.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 252,635 shares of the company's stock afterMarch 30, 2025 | marketbeat.comRaymond James Financial Inc. Makes New Investment in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Raymond James Financial Inc. bought a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 105,619 shares of the company's stockMarch 28, 2025 | marketbeat.comIonis Pharmaceuticals enters exclusive olezarsen license agreement with SobiMarch 27, 2025 | markets.businessinsider.comTeacher Retirement System of Texas Increases Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Teacher Retirement System of Texas increased its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 16.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 65,792 shares ofMarch 27, 2025 | marketbeat.comIonis expands partnership with Sobi to include olezarsen commercialization outside the U.S.March 26, 2025 | msn.comIs Ionis Pharmaceuticals, Inc. (IONS) a Promising Biotech Stock According to Wall Street AnalystsMarch 25, 2025 | msn.comJPMorgan Chase & Co. Cuts Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $45.00JPMorgan Chase & Co. decreased their target price on shares of Ionis Pharmaceuticals from $47.00 to $45.00 and set a "neutral" rating for the company in a research report on Monday.March 25, 2025 | marketbeat.comIonis Pharmaceuticals price target lowered to $45 from $47 at JPMorganMarch 24, 2025 | markets.businessinsider.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Recommendation of "Moderate Buy" by BrokeragesIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twenty ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold raMarch 24, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock Position Boosted by Swiss National BankSwiss National Bank raised its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 8.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 279,200 shares of the company's stock after acquiring an additional 2March 23, 2025 | marketbeat.comProficio Capital Partners LLC Makes New $829,000 Investment in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Proficio Capital Partners LLC purchased a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 23,703 shares of the company's stock, valued at approximately $829,000. Several other heMarch 23, 2025 | marketbeat.comSector Gamma AS Has $8.25 Million Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Sector Gamma AS lifted its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 11.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 235,842 shares of the company's stock after buying an additional 25,000 shares duringMarch 22, 2025 | marketbeat.comPrivium Fund Management B.V. Has $9.33 Million Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Privium Fund Management B.V. grew its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 6.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 266,794 shares of theMarch 20, 2025 | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Upgraded at StockNews.comStockNews.com raised Ionis Pharmaceuticals to a "sell" rating in a research note on Tuesday.March 19, 2025 | marketbeat.com Remove Ads Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address IONS Media Mentions By Week IONS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IONS News Sentiment▼0.860.78▲Average Medical News Sentiment IONS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IONS Articles This Week▼167▲IONS Articles Average Week Remove Ads Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BIIB News Today UTHR News Today INCY News Today BMRN News Today EXEL News Today NBIX News Today EXAS News Today HALO News Today RGEN News Today MDGL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IONS) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
